Influence of resveratrol associated with non-surgical periodontal treatment of patients with generalized aggressive periodontitis: clinical, microbiological, and immunoenzymatic analysis

• Grant number: 13/11973-0
• Support Opportunities: Scholarships in Brazil - Post-Doctoral
• Start date: October 01, 2013
• End date: February 29, 2016
• Field of knowledge: Health Sciences - Dentistry - Periodontology
• Principal Investigator: Márcio Zaffalon Casati
• Grantee: MONICA GRAZIELI CORREA DI GIORGI
• Host Institution: Vice-Reitoria de Pesquisa e Pós-Graduação. Universidade Paulista (UNIP). São Paulo , SP, Brazil

Abstract

The aim of the present clinical, randomized, placebo-controlled, double-blind, parallel study is to evaluate the effect of systemic administration of resveratrol as an adjunct to non-surgical periodontal treatment of patients with aggressive periodontitis, through clinical and enzyme immunoassays. For this, 32 subjects with generalized aggressive periodontitis will be selected and will be randomly allocated into two groups: control-ultrasonic debridement in one session, associated with systemic administration of placebo, for 180 days; - test- ultrasonic debridement in one session, associated with systemic administration of 500 mg of resveratrol, for 180 days. Before the beginning of treatment and after 3 and 6 months, samples will be taken to evaluate the gingival fluid levels of IL-1², IL-4, IL-6, IL-10 , IL-17, IL-23, TNF-± and IFN-³ by Luminex / MAGpix technique. In these same periods will be collected subgingival biofilm for the detection and quantification, by PCR-real time, the amounts of A. actinomycetencomitans, P. gingivalis, C. gingivalis, E. corrodens, T. forsythia, P. micros e P. intermedia. In the same periods of time blood samples will also be collected for analysis of serum levels of C-reactive protein ultrasensitive (hsCRP). Subsequently, data will be tested for normality (Kolmogorov-Smirnov test) and the statistical methods (parametric or non-parametric) will be indicated. A significance level of 5% will be adopted for all analysis.